See the DrugPatentWatch profile for inrebic
Medicare coverage for Inrebic (fedratinib) is not explicitly detailed in the provided information. However, Medicare generally covers prescription drugs administered in an outpatient setting, as well as those administered in a physician's office as part of a covered service [1]. For patients with myelofibrosis, the condition treated by Inrebic, Medicare coverage may depend on whether the drug is administered in a physician's office or hospital outpatient setting, and whether it is deemed medically necessary [2].
How is Inrebic typically administered?
Inrebic is an oral medication [3]. Patients typically take the drug by mouth, either at home or in a clinical setting, depending on their treatment plan and physician's recommendation [3].
What is Inrebic used to treat?
Inrebic is approved for the treatment of adults with intermediate-2 or high-risk primary or secondary myelofibrosis [3]. Myelofibrosis is a serious bone marrow disorder [4].
When does patent exclusivity expire for Inrebic?
Patent information for Inrebic, including expected expiry dates, can be found on DrugPatentWatch.com [5]. This site provides a database of drug patents and their associated timelines, which is crucial for understanding when generic versions might become available [5].